The use of systemic corticosteroid therapy could reduce mortality for hospitalized adults with community-acquired pneumonia, according to research published in the Annals of Internal Medicine.
The use of systemic corticosteroid therapy could reduce mortality for hospitalized adults with community-acquired pneumonia, according to research published in the Annals of Internal Medicine.
The investigators used data from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials and determined that patients hospitalized with community-acquired pneumonia benefited in multiple ways from the use of corticosteroids.
All-cause mortality fell from about 9% to 5% with the use of this therapy, which also was associated with a reduction in need for mechanical ventilation (by 5%), and acute respiratory distress syndrome. Corticosteroids also decreased time to clinical stability and duration of hospitalization by 1 day for these patients.
“Our study should lead to an important change in treatment for pneumonia,” lead author Reed A.C. Siemieniuk, MD, a physician and a graduate student at McMaster University, said in a statement. “Corticosteroids are inexpensive and readily available around the world. Millions of patients will benefit from this new evidence.”
Lower respiratory infections are the second-most common cause of premature mortality around the world, and community-acquired pneumonia is common in developed countries and can be severe as it is associated with acute respiratory distress syndrome and requires mechanical ventilation.
The international group of researchers (from Canada, Spain, Switzerland, and Norway) analyzed 13 randomized trials that included more than 2000 patients.
“Seldom do we see a major advance in treatment of a condition as common as community-acquired pneumonia,” said Gordon Guyatt, MD, MSc, the study’s senior investigator and a professor of clinical epidemiology and biostatistics at McMaster University. “Corticosteroids over short periods are safe, and we now know that they achieve important benefits in a serious and common medical illness.”
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More